Clinical Trial Update: A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating subcutaneous AMG 133 in adults with overweight or obesity has completed enrollment/status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• AMG 133

Snippet

Sponsor: Amgen | Conditions: Overweight, Obesity | Phase 1 | Status: COMPLETED